
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is experiencing a short-term headwind due to a shift toward genome testing. However, the company's new outpatient genome coverage policy has the potential to increase their average selling price by $100. Additionally, the company's ongoing execution and investment, including a tripling of their sales force, should help capitalize on the expanding market for genetic testing, particularly in pediatrics and rare diseases. The recent acquisition of Fabric Genomics, a genomic interpretation software business, could also provide additional revenue streams and help expand GeneDx's customer base globally. Overall, GeneDx's focus on genomics and commitment to advancing precision medicine positions them well for long-term success.
Bears say
GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services with a focus on whole exome and genome sequencing. However, its recent financial results have missed expectations due to headwinds from mix and softness in the non-core business. While the company has the potential to transform healthcare and drive improved outcomes with its genomic intelligence, there are risks associated with pricing and competition in its core businesses, as well as regulatory and operational execution risks. Additionally, GeneDx's expansion into new markets, such as pediatricians and newborn screening, may take time to convert early adopters and could present further operational risks.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares